Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - August 2025

Despite the ongoing turmoil over tariffs, medicine costs, and FDA policy, US wholesalers are performing well.

Pharma Wholesalers: Looking for Growth

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment explores how disciplined governance and forward-thinking models can safeguard profitability in a volatile market.

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

340B Litigation and the Path Toward Transparent Drug Discount Programs

Articles

Pharma Pulse 4/14/25:  How Deep Will Medicaid Cuts Go? Resonating with Younger Demographics & more

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

Steffen Lang, president, operations, executive committee member, Novartis, discusses what to expect from Novartis over the next decade in terms of technological innovations. 

LogiPharma Europe 2025: Driving Innovation in Core Therapeutic Areas

Senior Vice President, Market Development, at ConnectiveRx.

The key strategies for reducing or eliminating post-prescription abandonment.

From Prescription to Patient: Four Ways to Increase Speed to Therapy 

Founder and Principal Consultant at 1st Line Partners.

Why taking proactive steps—and combing the right data sources—is critical to informed decision-making in risk management.

What Your Data Can Tell You About Illicit Trade Risk

Steffen Lang, president, operations, executive committee member, Novartis, discusses how technology will continue to enhance operations and how it will impact patients. 

LogiPharma Europe 2025: Harnessing Technology to Advance Operations and Patient Impact

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, comments on another presentation that has caught her eye at the conference. 

Hubs East 2025: Building a Thriving Culture

The latest news for pharma industry insiders.

Pharma Pulse 4/11/25: Long-Term Sustainability for Diverse Trial Initiatives, Payers Consider Policy Options for GLP-1 Access & more

A look at the prevailing factors impacting treatment access in 2025.

Healthcare Scorecard from Patients with Chronic Illness

How pharma manufacturers can steadily navigate GTN components and                                             complexities when planning pharmacy benefit reimbursement.

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit

Steffen Lang, president, operations, executive committee member, Novartis, shares strategic insights on how pharma supply chain leaders can elevate operations to drive innovation, growth, and patient impact.

Featured Content

Pharmaceutical Commerce - August 2025

Pharma Wholesalers: Looking for Growth

Popping the Gross-to-Net Bubble, Part V: Innovative Pricing Models

340B Litigation and the Path Toward Transparent Drug Discount Programs